Faraz Ali - 03 Feb 2026 Form 4 Insider Report for Tenaya Therapeutics, Inc. (TNYA)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: TNYA
Reported as of: 03 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Feb 2026, 18:02:09 UTC
Prior SEC filing: 17 Nov 2025
Next SEC filing: 17 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Drimmer Rokovich, Attorney in Fact

Key filing fact

Faraz Ali filed Form 4 for Tenaya Therapeutics, Inc. (TNYA) on 05 Feb 2026.

Key facts

This page summarizes Faraz Ali's Form 4 filing for Tenaya Therapeutics, Inc. (TNYA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Feb 2026, 18:02.

Change

Previous filing in this sequence was filed on 17 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001667937 Primary reporting owner

Ali Faraz

Relationship: Chief Executive Officer, Director
Address: C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Jennifer Drimmer Rokovich, Attorney in Fact
Signature date: 05 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNYA transaction

Common Stock

Award

Transaction value: $0
Shares: +158,600
Change %: +53%
Price: $0.000000
Shares after: 458,266
Date: 03 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNYA transaction Derivative

Stock Option (Right to buy)

Award

Transaction value: $0
Shares: +952,250
Change %
Price: $0.000000
Shares after: 952,250
Date: 03 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 952,250
Exercise price: $0.9150
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.

Footnote F2

The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2026, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.

Footnote F3

Includes 369,875 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

Footnote F4

Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.